Teknova Reports First Quarter 2025 Financial Results

Core Insights - Alpha Teknova, Inc. reported total revenue of $9.8 million for the first quarter of 2025, reflecting a 5% increase from $9.3 million in the same period of 2024 [1][5] - The company introduced the proprietary PluriFreeze™ cryopreservation system in collaboration with Pluristyx, Inc., enhancing its cell therapy product portfolio [1][8] - Teknova reaffirmed its revenue guidance for 2025, expecting total revenue between $39 million and $42 million [1][11] Financial Performance - Lab Essentials revenue reached $8.1 million, a 12% increase from $7.3 million in Q1 2024, while Clinical Solutions revenue decreased by 32% to $1.2 million from $1.7 million [4][5] - Gross profit for Q1 2025 was $3.0 million, with a gross margin of 30.7%, up from 23.8% in Q1 2024, driven by higher revenue and lower overhead costs [6] - Operating expenses decreased to $8.0 million from $10.2 million in Q1 2024, primarily due to lower stock-based compensation and reduced spending [7] Cash Flow and Losses - The net loss for Q1 2025 was $4.6 million, or negative $0.09 per diluted share, compared to a net loss of $8.1 million, or negative $0.20 per diluted share, in Q1 2024 [9][21] - Adjusted EBITDA improved to negative $2.5 million from negative $3.8 million year-over-year, while free cash flow was negative $4.3 million, an improvement from negative $6.7 million in Q1 2024 [10][27] Strategic Developments - The collaboration with Pluristyx, Inc. positions Teknova as the exclusive manufacturer and distributor of the PluriFreeze™ product line in the U.S. and Canada, expanding its market reach [1][8] - The company maintains a strong cash position with total cash and short-term investments of $26.3 million and total borrowings of $13.2 million at the end of Q1 2025 [8]